| Nov 20 |
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
|
| Oct 24 |
Discovering Penny Stocks On US Exchanges: 3 Picks Under $100M Market Cap
|
| Oct 7 |
CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
|
| Oct 4 |
CytoMed Acquires Cord Blood Assets, Eyes Regenerative Medicine
|
| Oct 3 |
CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank
|
| Oct 1 |
CytoMed Therapeutics Limited reports 1H results
|
| Sep 30 |
CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates
|
| Sep 25 |
Presenting on the Emerging Growth Conference 75 Day 2 on September 26
|
| Aug 20 |
Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now
|
| Jul 17 |
CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
|
